Insmed Reports Strong Q1 2026 Earnings and BRINSUPRI Performance
In the first quarter of 2026, Insmed (INSM) reported strong performance for its product BRINSUPRI. The company reiterated a revenue guidance of at least $1 billion for the year and noted sequential growth of 44%, significantly outpacing industry averages. Key metrics included high payer approval rates, prescription refill frequency below the industry benchmark, and robust patient enrollment in support programs.
Tickers: $INSM
Topics: BRINSUPRI patient starts prescriber growth revenue guidance